Antibiotic resistance fund aims 2-4 new antibiotics by 2030, page-4

According to the published papers, PBT2 works in Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa, erythromycin-resistant group A Streptococcus (GAS), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) and gonorrhea. PBT2 makes the development of cross-resistance to medically important antimicrobials unlikely.

There are some leftovers, but it may be that they are not yet been tested. Pfizer and Novartis are the 2 biggest antibiotic producers and they have also enough money to get the PBT2 deal, TEVA is the 3rd but clearly smaller. Pfizer has been growing a lot last year ( COVID vaccination boom) and I think it is today the strongest of these candidates. An 8 billion growing market will interest all manufacturers.

The food industry will most likely also be using PBT2, but I have no understanding of those players. These 3 are not in that business.